5 active not recruiting, 4 completed, 4 recruiting, 3 unknown. 9 Phase 1, 5 Phase 3, 3 Phase 2, 1 Not applicable, 1 Phase 4.
Follow GC Biopharma Corp: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older vaccination of GC3114B, Vaccination of Efluelda - Influenza A, Influenza B, Influenza Vaccination | Phase 2 / Phase 3 | Not yet recruiting | GC Biopharma Corp | 1806 | 2026-10-01 | 2026-10-20 |
| A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years MG1111 (Barycela inj.), VARIVAX™ - Varicella (Chickenpox), Chickenpox Vaccine | Phase 3 | Recruiting | GC Biopharma Corp | 474 | 2026-03-17 | 2026-04-17 |
| A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults GC4006A, Normal Saline - COVID - 19 | Phase 1 | Active not recruiting | GC Biopharma Corp | 72 | 2026-01-28 | 2026-07-27 |
| A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults GC3111B, Boostrix® - Tetanus-diphtheria-acellular Pertussis (Tdap) | Phase 1 / Phase 2 | Recruiting | GC Biopharma Corp | 120 | 2025-06-05 | 2025-07-10 |
| A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease HM15421/GC1134A - Fabry Disesase | Phase 1 / Phase 2 | Recruiting | GC Biopharma Corp | 18 | 2025-05-14 | 2025-11-04 |
| Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) GC1130A - Sanfilippo Syndrome Type A | Phase 1 | Active not recruiting | GC Biopharma Corp | 9 | 2024-11-21 | 2026-09-08 |
| Evaluation of the Effectiveness and Safety of Rozetel Tablet in Patients After PCI: A Multi-Center Observational Study Hypertension, Dyslipidemia | Active not recruiting | GC Biopharma Corp | 1563 | 2023-06-07 | 2025-07-24 | |
| A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. Undiluted I.V.-Hepabig inj(GC5103), Diluted I.V.-Hepabig inj(GC5103) - Hepatitis B | Phase 3 | Recruiting | GC Biopharma Corp | 105 | 2023-04-13 | 2025-06-25 |
| A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2) - Healthy Volunteers | Phase 1 | Unknown | GC Biopharma Corp | 34 | 2023-02-06 | 2023-02-15 |
| An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years MG1111 - Varicella Zoster Virus Infection | Not applicable | Unknown | GC Biopharma Corp | 250 | 2023-02-01 | 2022-12-23 |
| A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2) - Healthy Volunteers | Phase 1 | Unknown | GC Biopharma Corp | 50 | 2023-01-17 | 2023-01-30 |
| A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ GC1123 - Mucopolysaccharidosis II, Hunter Syndrome | Phase 1 | Active not recruiting | GC Biopharma Corp | 12 | 2022-09-20 | 2024-10-15 |
| A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient MG1113 - Hemophilia | Phase 1 | Completed | GC Biopharma Corp | 15 | 2022-08-24 | 2025-11-24 |
| Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency GC5107 - Primary Immune Deficiency | Phase 3 | Active not recruiting | GC Biopharma Corp | 24 | 2020-12-21 | 2025-07-25 |
| IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies Rituximab, intravenous immune globulin - Renal Transplant | Phase 4 | Completed | Seoul National University Hospital | 50 | 2019-01-08 | 2022-10-26 |
| An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) Hunterase - MPS II, Hunter Syndrome (MPS II) | Phase 3 | Completed | GC Biopharma Corp | 30 | 2018-05-23 | 2026-01-15 |
| Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor Allogeneic NK cells - Malignant Lymphomas, Solid Tumors | Phase 1 | Completed | Seoul National University Hospital | 18 | 2010-09-01 | 2013-08-19 |
Chickenpox (2) · Mucopolysaccharidosis II (2) · COVID-19 (1) · Dyslipidemias (1) · Hemophilia A (1) · Hepatitis B (1) · Hypertension (1) · Influenza, Human (1) · Liver Diseases (1) · Lymphoma (1) · Mucopolysaccharidosis III (1) · Primary Immunodeficiency Diseases (1) · Sudden Infant Death (1) · Varicella Zoster Virus Infection (1)
Metformin (2) · Boostrix (1) · Chickenpox Vaccine (1) · Fluid Therapy (1) · Immunoglobulins, Intravenous (1) · Rituximab (1) · Saline Solution (1) · gamma-Globulins (1)
South Korea (14) · United States (3) · Argentina (1) · Bosnia and Herzegovina (1) · Serbia (1) · Thailand (1)
Eun-Jin Choi (1) · Jaeseok Yang, M.D., Ph.D. (1)